RGNX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

7.088

Open

7.040

VWAP

6.97

Vol

1.13M

Mkt Cap

362.40M

Low

6.820

Amount

7.87M

EV/EBITDA(TTM)

--

Total Shares

51.70M

EV

--

EV/OCF(TTM)

--

P/S(TTM)

--

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.

Show More

Events Timeline

(ET)

2026-05-14

16:30:00

Dow Rises 370 Points as Markets Optimistic on US-China Talks

2026-05-14

12:10:00

Dow Rises on Cisco Earnings, Market Optimism

2026-05-14

07:30:00

Regenxbio Reports Positive Results for RGX-202 in Duchenne Trial

2026-05-14

07:20:00

Regenxbio Expects Cash Reserves of $150.5M

2026-05-14

07:20:00

REGENXBIO Reports Q1 Revenue of $6.4M

2026-05-12 (ET)

2026-05-12

10:50:00

Trump Plans to Reduce Beef Import Tariffs

2026-05-11 (ET)

2026-05-11

12:30:00

Trump Approves Firing of FDA Commissioner Makary

News

NASDAQ.COM

05-22NASDAQ.COM

Multiple Companies Experience Significant Stock Price Gains

PRnewswire

05-18PRnewswire

REGENXBIO to Participate in Investor Conferences

seekingalpha

05-15seekingalpha

REGENXBIO Q1 2026 Earnings Call Highlights

Yahoo Finance

05-14Yahoo Finance

RGX-202 Clinical Trial Achieves Significant Success

stocktwits

05-14stocktwits

REGENXBIO Q1 Results Fall Short of Expectations Amid FDA Concerns

seekingalpha

05-14seekingalpha

Regenxbiopress Reports Q1 2026 Financial Results with Significant Losses

7 Analyst Rating

Wall Street analysts forecast RGNX stock price to rise

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

19.00

Averages

29.71

High

45.00

Current: 0.000

Low

19.00

Averages

29.71

High

45.00

Morgan Stanley

Overweight

to

Overweight

downgrade

$17 -> $16

AI Analysis

2026-05-15

Reason

Morgan Stanley

Price Target

$17 -> $16

AI Analysis

2026-05-15

downgrade

Overweight

to

Overweight

Reason

Morgan Stanley lowered the firm's price target on Regenxbio to $16 from $17 and keeps an Overweight rating on the shares.

BofA

Buy

downgrade

$25 -> $14

2026-05-15

Reason

BofA

Price Target

$25 -> $14

2026-05-15

downgrade

Buy

Reason

BofA lowered the firm's price target on Regenxbio to $14 from $25 and keeps a Buy rating on the shares. The firm views the RGX-202 AFFINITY DUCHENNE topline update as "directionally encouraging despite some questions about safety and regulatory path," but reduced its peak penetration estimate and view of the odds of success for DMD due to regulatory uncertainty despite what it calls "an objectively positive topline result from the study."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RGNX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Regenxbio Inc (RGNX.O) is 0.00, compared to its 5-year average forward P/E of 1.96. For a more detailed relative valuation and DCF analysis to assess Regenxbio Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

1.96

Current PE

0.00

Overvalued PE

22.35

Undervalued PE

-18.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.36

Current EV/EBITDA

-0.11

Overvalued EV/EBITDA

13.24

Undervalued EV/EBITDA

-15.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

5.23

Current PS

1.26

Overvalued PS

8.46

Undervalued PS

2.01

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

news about stocks that are below 10 dollar

Intellectia · 100 candidates

Region: USPrice: $1.00 - $10.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000News Driver: Positive, Negative

Ticker

Name

Market Cap$

XWELL Inc

6.98M

Larimar Therapeutics Inc

494.39M

VS Media Holdings Ltd

5.06M

Evolent Health Inc

350.52M

Navitas Semiconductor Corp

2.27B

Sharplink Inc

1.46B

update list for stock prices between 5-50

Intellectia · 64 candidates

Price: $5.00 - $50.00Moving Average Relationship: PriceBelowMA20Week Price Change Pct: <= $-7.00Month Price Change Pct: <= $-10.00Monthly Average Dollar Volume: >= 800,000

Ticker

Name

Market Cap$

Venu Holding Corp

364.84M

Regenxbio Inc

698.09M

Anbio Biotechnology

2.89B

SMX (Security Matters) PLC

156.97M

Northrim BanCorp Inc

510.78M

Array Digital Infrastructure Inc

4.03B

Whales Holding RGNX

Voss Capital, LP

Redmile Group, LLC

Integral Health Asset Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Regenxbio Inc (RGNX) stock price today?

The current price of RGNX is 7.01 USD — it has increased 1.74

What is Regenxbio Inc (RGNX)'s business?

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.

What is the price predicton of RGNX Stock?

Wall Street analysts forecast RGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGNX is29.71 USD with a low forecast of 19.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Regenxbio Inc (RGNX)'s revenue for the last quarter?

Regenxbio Inc revenue for the last quarter amounts to 6.39M USD, decreased -92.82

What is Regenxbio Inc (RGNX)'s earnings per share (EPS) for the last quarter?

Regenxbio Inc. EPS for the last quarter amounts to -1.72 USD, decreased -1533.33

How many employees does Regenxbio Inc (RGNX). have?

Regenxbio Inc (RGNX) has 371 emplpoyees as of May 31 2026.

What is Regenxbio Inc (RGNX) market cap?

Today RGNX has the market capitalization of 362.40M USD.